利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

394 条记录 (耗时 0.054 秒)

    HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH
    171.
    发明申请
    HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH 审中-公开
    羟基取代的氨基酸，其组合物及其处理方法

    公开(公告)号：US20130225564A1

    公开(公告)日：2013-08-29

    申请号：US13845180

    申请日：2013-03-18

    申请人： Signal Pharmaceuticals, LLC

    发明人： STEVEN CLAREEN ,  VERONIQUE PLANTEVIN-KRENITSKY ,  MOORTHY PALANKI ,  YOSHITAKA SATOH

    IPC分类号： C07D473/32

    CPC分类号： C07D473/32 ,  A61K31/52

    摘要： Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

    摘要翻译： 本文提供具有以下结构的氨基嘌呤化合物：其中R1，R2和R3如本文所定义，包含有效量的氨基嘌呤化合物的组合物和治疗或预防癌症，心血管疾病，肾脏疾病，自身免疫病症， 炎性病症，黄斑变性，缺血再灌注损伤，疼痛和相关综合征，疾病相关性消耗，石棉相关病症，肺动脉高压或通过抑制JNK途径可治疗或可预防的病症包括给予有效量的氨基嘌呤 与需要的患者复合。

    Methods of modulating inflammatory cell recruitment and gene expression using haloaryl substituted aminopurines
    172.
    发明授权
    Methods of modulating inflammatory cell recruitment and gene expression using haloaryl substituted aminopurines 有权
    使用卤代芳基取代氨基嘌呤调节炎性细胞募集和基因表达的方法

    公开(公告)号：US08440661B2

    公开(公告)日：2013-05-14

    申请号：US12779083

    申请日：2010-05-13

    申请人： Brydon L. Bennett ,  Kate Northcote ,  Brian Edwin Cathers

    发明人： Brydon L. Bennett ,  Kate Northcote ,  Brian Edwin Cathers

    IPC分类号： A61P11/00 ,  C07D473/32 ,  C07D239/50 ,  C07D239/48 ,  A61K31/53 ,  A61P3/10

    CPC分类号： C07D473/32 ,  A61K31/52

    摘要： Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

    摘要翻译： 本文提供具有以下结构的氨基嘌呤化合物：其中R1，R2和R3如本文所定义，包含有效量的氨基嘌呤化合物的组合物和治疗或预防癌症，心血管疾病，肾脏疾病，自身免疫病症， 炎性病症，黄斑变性，缺血再灌注损伤，疼痛和相关综合征，疾病相关性消耗，石棉相关病症，肺动脉高压或通过抑制JNK途径可治疗或可预防的病症包括给予有效量的氨基嘌呤 与需要的患者复合。

    HIV inhibiting bicyclic pyrimdine derivatives
    175.
    发明授权
    HIV inhibiting bicyclic pyrimdine derivatives 有权

    公开(公告)号：US08153640B2

    公开(公告)日：2012-04-10

    申请号：US11718181

    申请日：2005-10-27

    申请人： Jerôme Emile Georges Guillemont ,  Mikaël Paugam ,  Bruno Francois Marie Delest ,  Jan Heeres ,  Paulus Joannes Lewi ,  Paul Adriaan Jan Janssen ,  Frank Xavier Jozef Herwig Arts, legal representative

    发明人： Jerôme Emile Georges Guillemont ,  Mikaël Paugam ,  Bruno Francois Marie Delest ,  Jan Heeres ,  Paulus Joannes Lewi ,  Paul Adriaan Jan Janssen

    IPC分类号： C07D473/32 ,  A61K31/52 ,  A61P31/18

    CPC分类号： C07D487/04 ,  C07D473/00 ,  C07D473/16 ,  C07D473/24 ,  C07D473/34

    摘要： HIV replication inhibitors of formula N-oxides, pharmaceutically acceptable addition salts, quaternary amines or stereoisomeric forms thereof, wherein -a1=a2-a3=a4- is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; -b1=b2-b3=b4- is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; n and m is 0, 1, 2, 3 and in certain cases also 4; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; optionally substituted C1-6alkyl; C1-6alkyloxycarbonyl; R2 is OH; halo; optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl; substituted carbonyl; carboxyl; CN; nitro; amino; substituted amino; polyhalomethyl; polyhalomethylthio; —S(═O)pR6; C(═NH)R6; R2a is CN; amino; substituted amino; optionally substituted C1-6alkyl; halo; optionally substituted C1-6alkyloxy; substituted carbonyl; —CH═N—NH—C(═O)—R16; optionally substituted C1-6alkyloxyC1-6alkyl; substituted C2-6alkenyl or C2-6alkynyl; —C(═N—O—R8)—C1-4alkyl; R7 or —X—R7; R3 is CN; amino; C1-6alkyl; halo; optionally substituted C1-6alkyloxy; substituted carbonyl; —CH═N—NH—C(═O)—R16; substituted C1-6alkyl; optionally substituted C1-6alkyloxyC1-6alkyl; substituted C2-6alkenyl or C2-6alkynyl; —C(═N—O—R8)—C1-4alkyl; R7; —X—R7; R4 is halo; OH; optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl; C3-7cycloalkyl; C1-6alkyloxy; CN; nitro; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; substituted carbonyl; formyl; amino; mono- or di(C1-4alkyl)amino or R7; -A-B— is —CR5═N—, —N═N—, —CH2—CH2—, —CS—NH—, —CO—NH—, —CH═CH—; pharmaceutical compositions comprising these; methods for the preparation of these compounds and compositions; the use of these compounds for the prevention or the treatment of HIV infection.